BRPI0516889A - composição para o tratamento da obesidade e hiperlipidemia - Google Patents

composição para o tratamento da obesidade e hiperlipidemia

Info

Publication number
BRPI0516889A
BRPI0516889A BRPI0516889-9A BRPI0516889A BRPI0516889A BR PI0516889 A BRPI0516889 A BR PI0516889A BR PI0516889 A BRPI0516889 A BR PI0516889A BR PI0516889 A BRPI0516889 A BR PI0516889A
Authority
BR
Brazil
Prior art keywords
absorption
fat
composition
hyperlipidemia
obesity
Prior art date
Application number
BRPI0516889-9A
Other languages
English (en)
Inventor
Jorge Luis Rosado Loria
Miguel Angel Duarte Vasquez
Original Assignee
Jorge Luis Rosado Loria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36228057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jorge Luis Rosado Loria filed Critical Jorge Luis Rosado Loria
Publication of BRPI0516889A publication Critical patent/BRPI0516889A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçãO PARA O TRATAMENTO DA OBESIDADE E HIPERLIPIDEMIA. Onde a composição farmacêutica da presente invenção reduz a absorção de gordura proveniente da dieta através da inibição da enzima lipase gastrintestinal. Os inibidores utilizados são a polilisina e a protamina, ambas moléculas carregadas positivamente e têm a capacidade de interagir com o substrato emulsificado e impedir a absorção da enzima na interfase inibindo desta forma sua atividade. A combinação do inibidor de lipase com o polímero coletor de gordura (quitosano), aumenta o efeito inibidor da absorção de gordura, tal efeito sinérgico é atribuído à aceleração do trânsito gastrintestinal do alimento produzido pelo polímero insolúvel.
BRPI0516889-9A 2004-10-28 2005-07-18 composição para o tratamento da obesidade e hiperlipidemia BRPI0516889A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA04010692A MXPA04010692A (es) 2004-10-28 2004-10-28 Composicion para el tratamiento de la obesidad e hiperlipidemia.
PCT/MX2005/000058 WO2006046847A1 (es) 2004-10-28 2005-07-18 Composición para el tratamiento de la obesidad e hiperlipidemia

Publications (1)

Publication Number Publication Date
BRPI0516889A true BRPI0516889A (pt) 2008-09-23

Family

ID=36228057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516889-9A BRPI0516889A (pt) 2004-10-28 2005-07-18 composição para o tratamento da obesidade e hiperlipidemia

Country Status (4)

Country Link
US (1) US8324185B2 (pt)
BR (1) BRPI0516889A (pt)
MX (1) MXPA04010692A (pt)
WO (1) WO2006046847A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007039428A (ja) * 2005-06-30 2007-02-15 Ehime Univ 体重増加抑制剤
JP4889782B2 (ja) 2008-12-24 2012-03-07 株式会社マルハニチロ食品 プロタミン及び／またはその塩と酸性高分子化合物とを含む生理活性複合体及びその用途
JP4493725B1 (ja) * 2009-10-02 2010-06-30 株式会社 ファイナルフューチャーインターナショナル 脂肪分解促進作用を有する組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
PT1105123E (pt) * 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano

Also Published As

Publication number Publication date
US20090197831A1 (en) 2009-08-06
US8324185B2 (en) 2012-12-04
MXPA04010692A (es) 2006-05-02
WO2006046847A1 (es) 2006-05-04

Similar Documents

Publication Publication Date Title
Yang et al. Antimetastatic effects of Terminalia catappa L. on oral cancer via a down-regulation of metastasis-associated proteases
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
BRPI0412254A (pt) produtos aril-heteroaromáticos, composições que os contêm e utilização
WO2010074588A8 (en) Pharmaceutical compounds
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
WO2008127274A3 (en) Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
BR112021016879A2 (pt) Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo leuconostoc citreum wikim0104
EP2913322A3 (en) Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same
WO2007146730A3 (en) Deacetylase inhibitor therapy
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
BR112013025630A2 (pt) derivados de piridopirazina e seu uso
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
EA201070746A1 (ru) Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
WO2007115805A3 (en) Aurora kinase inhibitors
Ryu et al. Sulfated chitooligosaccharide II (SCOS II) suppress collagen degradation in TNF-induced chondrosarcoma cells via NF-κB pathway
BR112012006872A2 (pt) composição, promotor de lipólise oral, inibidor de enzima de conversão de angiotensina oral, e, alimento ou bebida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]